- Home
- BOWN vs FEMY Comparison
BOWN vs FEMY Comparison
Compare BOWN & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOWN
- FEMY
- Stock Information
- Founded
- BOWN 2023
- FEMY 2004
- Country
- BOWN United States
- FEMY United States
- Employees
- BOWN N/A
- FEMY N/A
- Industry
- BOWN
- FEMY Medical/Dental Instruments
- Sector
- BOWN
- FEMY Health Care
- Exchange
- BOWN Nasdaq
- FEMY Nasdaq
- Market Cap
- BOWN 28.5M
- FEMY 29.9M
- IPO Year
- BOWN 2023
- FEMY 2021
- Fundamental
- Price
- BOWN $9.19
- FEMY $0.94
- Analyst Decision
- BOWN
- FEMY Strong Buy
- Analyst Count
- BOWN 0
- FEMY 3
- Target Price
- BOWN N/A
- FEMY $8.67
- AVG Volume (30 Days)
- BOWN 2.6K
- FEMY 259.3K
- Earning Date
- BOWN 01-01-0001
- FEMY 08-07-2025
- Dividend Yield
- BOWN N/A
- FEMY N/A
- EPS Growth
- BOWN N/A
- FEMY N/A
- EPS
- BOWN 0.02
- FEMY N/A
- Revenue
- BOWN N/A
- FEMY $1,699,232.00
- Revenue This Year
- BOWN N/A
- FEMY $283.83
- Revenue Next Year
- BOWN N/A
- FEMY $161.03
- P/E Ratio
- BOWN $201.25
- FEMY N/A
- Revenue Growth
- BOWN N/A
- FEMY 61.97
- 52 Week Low
- BOWN $2.71
- FEMY $0.69
- 52 Week High
- BOWN $19.77
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- BOWN 43.15
- FEMY 50.13
- Support Level
- BOWN $9.14
- FEMY $0.91
- Resistance Level
- BOWN $9.20
- FEMY $0.99
- Average True Range (ATR)
- BOWN 0.38
- FEMY 0.05
- MACD
- BOWN -0.04
- FEMY 0.00
- Stochastic Oscillator
- BOWN 38.89
- FEMY 28.50
About BOWN Bowen Acquisition Corp
Bowen Acquisition Corp is a blank check company.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.